Navigation Links
Bone drug is mixed blessing for breast cancer patients
Date:9/26/2011

A drug used to protect bone may extend survival in older breast cancer patients, according to researchers at the Universities of Sheffield and Leeds.

The AZURE trial, led by Professor Robert Coleman from the University of Sheffield, has revealed that the bisphosphonate drug zoledronic acid boosts disease-free survival in postmenopausal breast cancer patients but may have an adverse effect on younger women.

The full results of the trial were presented today (25 September 2011) at the European Multidisciplinary Cancer Congress in Stockholm and subsequently published in the New England Journal of Medicine.

Bisphosphonate drugs, like zoledronic acid, are used mainly to treat osteoporosis. However, they may also be given to breast cancer patients to protect against the effects of secondary bone cancer.

The trial, which started in 2003, involved 3,360 women with early breast cancer from 174 centres in the UK, Australia, Spain, Ireland, Portugal, Taiwan and Thailand. Patients were randomised to receive standard chemotherapy and/or endocrine therapy (hormone therapy) for their breast cancer, to try and prevent recurrence or spread of the disease, with or without zoledronic acid.

Contrary to previous studies, there was no significant difference in disease-free or overall survival between patients who received zoledronic acid and those that did not, looking at the study population as a whole. However, the addition of zoledronic acid did bring significant benefits to an important subgroup of women within the trial.

The study revealed that women who had completely passed through the menopause (five years since last period) had significantly improved disease-free and overall survival. Here, the overall survival rate at five years was 85 per cent compared to 79 per cent for women who did not receive zoledronic acid. The benefit was independent of the characteristics of the disease as defined by the stage of the tumour, oestrogen receptor status, and lymph node involvement. For all other patients, overall five year survival was similar at 86 per cent in the zoledronic acid group and 85 per cent in the control group.

Most surprisingly, it was the recurrence rates outside bone that were most profoundly affected by the zoledronic acid with clear benefit in the postmenopausal women but a possible adverse effect in younger women. The relative risk for developing metastases outside bone during treatment with zoledronic acid was approximately halved in the postmenopausal women compared with the younger patients (p <.001).

The results shed new light on the role that the bones may play in the progress of the disease. The effects on metastasis and recurrence outside bone suggests that the bone marrow is an important sanctuary for tumour cells which can be activated after sometimes many years of dormancy. With help from bone marrow stem cells, these previously dormant tumour cells may then spread via the blood stream to set up metastases at other sites.

Other studies in postmenopausal women and younger women given treatment to induce a menopause with hormone sensitive breast cancer have also indicated benefit for zoledronic acid in early breast cancer.

The AZURE trial is the first study to evaluate the use of zoledronic acid in a broad range of patients. Further data from other similar trials are anticipated later this year.

Professor Robert Coleman said: "The results have shown that zoledronic acid should not be used routinely for the treatment of early breast cancer. However, for those with low levels of female hormones, due either to natural ageing or specific treatments to induce menopause, the approach appears very promising as more women go on to rid themselves of the disease.

"Our findings could mean a major new treatment approach for the tens of thousands of women in the UK who develop breast cancer. We are now investigating the hormone levels in blood and the biology of the breast tumours in samples donated by the AZURE patients to help us better understand the reasons behind our results."

Helen Marshall, Principal Statistician from the University of Leeds' Clinical Trials Research Unit (CTRU), said: "The statistics of this analysis are complex and the results need to be interpreted with a degree of caution. The size and significance of the difference by menopausal status suggests that this finding is genuine, but we will need to carry out further studies to substantiate this exciting result."


'/>"/>

Contact: Shemina Davis, Media Relations Officer
shemina.davis@sheffield.ac.uk
01-142-225-339
University of Sheffield
Source:Eurekalert

Related medicine news :

1. Extending lifespan has mixed effects on learning and memory
2. U.S. Report on Kids Health Brings Mixed Results
3. Antibiotics a Mixed Bag for Kids Ear Infections: Analysis
4. Elder law expert: Health care reform act a mixed bag for seniors
5. Americas Health a Mixed Bag: Report
6. Models Photos May Spur Mixed Messages About Body Image
7. Trials of Type 1 Diabetes Vaccines Bring Mixed Results
8. Master Zhi Gang Sha Dedicates Soul Healing Blessings for Humanity Service to Chile's Earthquake Victims
9. Supporters and opponents of a special blessing for homosexuals share many values
10. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
11. Low forms of cyclin E reduce breast cancer drugs effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global ... is recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, ... move to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice ...
(Date:1/21/2017)... Pekin, IL (PRWEB) , ... January 21, 2017 , ... ... disorders. Even when individuals experience the freedom of recovery, they often feel shame for ... abuse and post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing in the ... is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of ... asked of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology: